C I. Mockridge
Southampton, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications
Gas-phase unfolding assay rapidly predicts structure-function relationships in engineered antibodies with tuned flexibilities.
Journal: Nature communications
Published: August 22, 2025
Harnessing multivalency and FcγRIIB engagement to augment anti-CD27 immunotherapy.
Journal: Nature communications
Published: December 10, 2024
Structure-guided disulfide engineering restricts antibody conformation to elicit TNFR agonism.
Journal: Nature communications
Published: July 23, 2024
Impact of isotype on the mechanism of action of agonist anti-OX40 antibodies in cancer: implications for therapeutic combinations.
Journal: Journal for immunotherapy of cancer
Published: May 16, 2024
Fcγ receptor binding is required for maximal immunostimulation by CD70-Fc.
Journal: Frontiers in immunology
Published: July 03, 2023
Reducing affinity as a strategy to boost immunomodulatory antibody agonism.
Journal: Nature
Published: February 22, 2022
FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms.
Journal: Cell reports
Published: February 20, 2022
Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.
Journal: Journal for immunotherapy of cancer
Published: December 08, 2021
TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity.
Journal: Communications biology
Published: February 05, 2021
Domain binding and isotype dictate the activity of anti-human OX40 antibodies.
Journal: Journal for immunotherapy of cancer
Published: November 24, 2020
LILRB3 (ILT5) is a myeloid cell checkpoint that elicits profound immunomodulation.
Journal: JCI insight
Published: June 22, 2020
Last Updated: 09/26/2026